Your browser doesn't support javascript.
Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka.
Jeewandara, Chandima; Aberathna, Inoka Sepali; Danasekara, Saubhagya; Gomes, Laksiri; Fernando, Suranga; Guruge, Dinuka; Ranasinghe, Thushali; Gunasekera, Banuri; Kamaladasa, Achala; Kuruppu, Heshan; Somathilake, Gayasha; Jayamali, Jeewantha; Jayathilaka, Deshni; Wijayatilake, Helanka Dinesh Kumara; Pushpakumara, Pradeep Darshana; Harvie, Michael; Nimasha, Thashmi; de Silva, Shiromi Devika Grace; Wijayamuni, Ruwan; Schimanski, Lisa; Rijal, Pramila; Tan, Jack; Townsend, Alain; Ogg, Graham S; Malavige, Gathsaurie Neelika.
  • Jeewandara C; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Aberathna IS; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Danasekara S; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Gomes L; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Fernando S; Ministry of Health, Colombo, Sri Lanka.
  • Guruge D; Colombo Municipal Council, Colombo, Sri Lanka.
  • Ranasinghe T; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Gunasekera B; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Kamaladasa A; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Kuruppu H; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Somathilake G; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Jayamali J; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Jayathilaka D; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Wijayatilake HDK; Ministry of Health, Colombo, Sri Lanka.
  • Pushpakumara PD; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Harvie M; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • Nimasha T; Allergy Immunology and Cell Biology Unit, Department of Immunology and Molecular Medicine, University of Sri Jayewardenepura, Nugegoda, Sri Lanka.
  • de Silva SDG; Colombo Municipal Council, Colombo, Sri Lanka.
  • Wijayamuni R; Ministry of Health, Colombo, Sri Lanka.
  • Schimanski L; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Rijal P; Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
  • Tan J; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Townsend A; Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
  • Ogg GS; MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
  • Malavige GN; Centre for Translational Immunology, Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK.
Immunology ; 167(2): 263-274, 2022 10.
Article in English | MEDLINE | ID: covidwho-1909393
ABSTRACT
To determine the antibody responses elicited by different vaccines against SARS-CoV-2, we compared antibody responses in individuals 3 months post-vaccination in those who had received different vaccines in Sri Lanka. Abs to the receptor binding domain (RBD) of the ancestral (wild type) virus (WT) as well as to variants of concern (VoCs), and ACE2 blocking Abs, were assessed in individuals vaccinated with Moderna (n = 225), Sputnik V (n = 128) or Sputnik light (n = 184) and the results were compared with previously reported data on Sinopharm and AZD1222 vaccinees. A total of 99.5% of Moderna, >94% of AZD1222 or Sputnik V and >70% of Sputnik light, >60% of Sinopharm vaccine recipients, had a positive response to ACE2 blocking antibodies. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/AZD1222 (had equal levels) > Sputnik light > Sinopharm. All Moderna recipients had antibodies to the RBD of WT, alpha and beta, while positivity rates for delta variant was 80%. The positivity rates for Sputnik V vaccinees for the WT and VoCs were higher than for AZD1222 vaccinees while those who received Sinopharm had the lowest positivity rates (<16.7%). The total antibodies to the RBD were highest for the Sputnik V and AZD1222 vaccinees. The Moderna vaccine elicited the highest ACE2 blocking antibody levels followed by Sputnik V/AZD1222, while those who received Sinopharm had the lowest levels. These findings highlight the need for further studies to understand the effects on clinical outcomes.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Immunology Year: 2022 Document Type: Article Affiliation country: Imm.13535

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Prognostic study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia Language: English Journal: Immunology Year: 2022 Document Type: Article Affiliation country: Imm.13535